- Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)2011 | Second Faculty of Medicine
- Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study2018 | Second Faculty of Medicine
- Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma2018 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study2020 | Faculty of Medicine in Hradec Králové
- Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 20042013 | Second Faculty of Medicine
- Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group2015 | Central Library of Charles University
- Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel2012 | Second Faculty of Medicine
- Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era2010 | First Faculty of Medicine
- Allogeneic stem cell transplantation can improve outcome of AML patients without complete cytogenetic response after induction and consolidation treatment2015 | Faculty of Medicine in Pilsen
- AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity2005 | Second Faculty of Medicine
- Favorable outcome in infants with AML after intensive first- nd second-line treatment: an AML-BFM study group report2012 | Second Faculty of Medicine
- The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents2014 | First Faculty of Medicine
- Experimental therapy of B-cell Non-Hodgkin's lymphonasPublication without faculty affiliation
- Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 982006 | Second Faculty of Medicine
- Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission2018 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial2007 | Second Faculty of Medicine
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial2023 | Publication without faculty affiliation
